Axovant Sciences to Present at Upcoming Scientific Meetings

BASEL, Switzerland, March 21, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at the American Association for Geriatric Psychiatry (AAGP) Annual Meeting being held in Dallas March 24-27 and at the American Academy of Neurology (AAN) Annual Meeting being held in Boston April 22-28.

AAGP Annual Meeting

The company will present the following:

Intepirdine (RVT-101), a 5-HT6 Receptor Antagonist, as an Adjunct to Donepezil in Mild-to-Moderate Alzheimer's Disease: Evaluation of Activities of Daily Living Domains 
Date: March 26, 2017             11:30 A.M. – 6:45 P.M. ET
Location: Hilton Anatole Hotel Grand Ballroom
Abstract Number: NR 5

Examining the Clinical Profile of Nelotanserin, a Novel Agent in Development for Lewy Body Dementia
Date: March 26, 2017             11:30 A.M. – 6:45 P.M. ET
Location: Hilton Anatole Hotel Grand Ballroom
Abstract Number: NR 15

AAN Annual Meeting

The company will present the following:

An Assessment of Dependence in Dementia Using A Conversion Algorithm of ADCS-ADL to Dependence Scale From a Double Blind Placebo Controlled Trial of Intepirdine (RVT-101)
Date: April 25, 2017   8:30 A.M. – 7:00 P.M. ET
Location: Boston Convention and Exhibition Center 
Abstract Number: P3-088

A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson's Disease Dementia Subjects Experiencing Visual Hallucinations
Date: April 28, 2017   8:30 A.M. – 5:30 P.M. ET
Location: Boston Convention and Exhibition Center 
Abstract Number: P6-088

Axovant expects to present detailed results from both Phase 2 studies of nelotanserin in Lewy body dementia patients in the second half of 2017 following the completion of both studies.

Forward Looking Statement
This press release contains forward-looking statements, including statements regarding Axovant's clinical development and regulatory strategy for intepirdine and nelotanserin. Forward-looking statements can be identified by the words "believe," "anticipate," "continue," "estimate," "project," "expect," "plan," "potential," "intend," "will," "would," "could," "should" or the negative or plural of these words or other similar expressions that are predictions or indicate future events, trends or prospects.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of intepirdine and nelotanserin; and increased regulatory requirements. These statements are subject to the risk that clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share Axovant's views of the clinical study data. In addition, promising interim results or other preliminary analyses do not in any way ensure that later or final results in a clinical trial or in related or similar clinical trials will replicate those interim results. The product discussed is investigational and not approved and there can be no assurance that the clinical program for intepirdine or nelotanserin will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that any of our product candidates will ever receive regulatory approval or be successfully commercialized.

For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Axovant's business in general, see the "Risk Factors" section of our quarterly report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2017, and other filings that Axovant makes with the SEC from time to time. These forward-looking statements are based on information available to Axovant as of the date of this press release and speak only as of the date of this release. Axovant disclaims any obligation to update these forward-looking statements, except as may be required by law.

About Axovant Sciences
Axovant Sciences is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of this condition.

SOURCE Axovant Sciences Ltd.

Related Links

http://www.axovant.com